Fluocinolone Acetonide

Patients with noninfectious uveitis affecting the posterior segment who were treated with a fluocinolone acetonide intravitreal implant experienced beneficial effects on macular edema through 36 months.

In this video from the virtual American Society of Retina Specialists meeting, Caesar Luo, MD, discusses the progression of retinal disease in eyes of patients lost to follow-up for at least 6 months.

In this video from the virtual American Society of Retina Specialists meeting, Dilraj Grewal, MD, MBBS, discusses a study evaluating the recurrence of uveitis after treatment with the Yutiq insert from EyePoint Pharmaceuticals.

Real-world long-term study outcomes showed sustained safety and efficacy of Iluvien in patients with diabetic macular edema.

Alimera Sciences has entered into a new $45 million term loan agreement with Solar Capital Partners, refinancing its debt facility, according to a press release.

Iluvien has been approved by the governmental agencies overseeing medical products in Belgium, the Netherlands and Luxemburg, Alimera Sciences announced in a press release.

SAN FRANCISCO — At the American Academy of Ophthalmology meeting, Matthew Manry, MD, discusses his poster presentation on the findings of reimplantation of Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg, Alimera Sciences) in the treatment of diabetic macular edema.

SAN FRANCISCO — At the American Academy of Ophthalmology meeting, Caesar K. Luo, MD, FACS, discusses global safety signals in the use of fluocinolone acetonide implants for the treatment of diabetic macular edema.

Alimera Sciences and Horus Pharma have expanded a distribution agreement to allow Horus to introduce Iluvien for diabetic macular edema and noninfectious posterior uveitis in the Benelux countries of Belgium, the Netherlands and Luxembourg, according to a press release.

CHICAGO — At the American Society of Retina Specialists meeting, Victor H. Gonzalez, MD, summarizes a trial on the real-world use of Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg, Alimera Sciences) in patients with diabetic macular edema and the predictability of what happens to IOP in patients with the implant who require supplemental steroids.